Robert Nelsen

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Chicago, IL
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Ryan Brown, attorney-in-fact
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Robert Nelsen

Form 4 holding Director

Denali Therapeutics Inc.

Security class
Common Stock
Shares / value
9,668,749
Estimated value
$178,098,357
Report date
02 Jun 2021
Price
$18.42
Ownership
Held by ARCH Venture Fund VIII, L.P.
Form 4 holding Director, 10%+ Owner

Lyell Immunopharma, Inc.

Security class
Common Stock
Shares / value
18,206,358
Estimated value
$41,510,496
Report date
14 Jun 2024
Price
$2.28
Ownership
ARCH Venture Fund IX,L.P.
Form 4 holding Director, 10%+ Owner

Lyell Immunopharma, Inc.

Security class
Common Stock
Shares / value
18,206,358
Estimated value
$41,510,496
Report date
14 Jun 2024
Price
$2.28
Ownership
ARCH Venture Fund IX Overage, L.P.
Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
6,128,297
Estimated value
$26,658,091
Report date
01 Aug 2025
Price
$4.35
Ownership
By ARCH Venture Fund X Overage, L.P.
Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
6,230,300
Estimated value
$20,559,990
Report date
01 Aug 2025
Price
$3.30
Ownership
By ARCH Venture Fund XII, L.P.
Form 4 holding Director

Vir Biotechnology, Inc.

Security class
Common Stock
Shares / value
584,148
Estimated value
$5,524,697
Report date
30 May 2024
Price
$9.46
Ownership
Direct
Form 4 holding Director

Vir Biotechnology, Inc.

Security class
Common Stock
Shares / value
33,893
Estimated value
$320,550
Report date
30 May 2024
Price
$9.46
Ownership
Indirect
Form 4 holding Director

Denali Therapeutics Inc.

Security class
Common Stock
Shares / value
12,432
Estimated value
$228,997
Report date
02 Jun 2021
Price
$18.42
Ownership
Direct
Form 4 holding Director

Vir Biotechnology, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
16,000
Estimated value
$24,480
Report date
30 May 2024
Price
$1.53
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Lyell Immunopharma, Inc.

Security class
Option (right to buy)
Shares / value
130,000
Estimated value
Report date
14 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Sana Biotechnology, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
90,000
Estimated value
Report date
04 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Prime Medicine, Inc.

Security class
Stock Option (right to buy)
Shares / value
75,000
Estimated value
Report date
05 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Denali Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
6,222
Estimated value
Report date
02 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Denali Therapeutics Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
01 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Robert Nelsen

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .